Cagrilintide is a long-acting amylin analog that represents an important addition to the metabolic peptide research toolkit. As interest grows in combination approaches to metabolic research — particularly Cagrilintide + semaglutide — this peptide has gained significant attention for its unique mechanism of action targeting satiety and gastric regulation through the amylin pathway.
What is Cagrilintide?
Cagrilintide is a synthetic analog of human amylin (islet amyloid polypeptide, IAPP), a 37-amino acid hormone co-secreted with insulin by pancreatic beta cells. Native amylin has a very short half-life, but Cagrilintide's modifications extend its duration of action to approximately one week, making it practical for sustained-exposure research protocols.
Mechanism of Action
Cagrilintide acts through amylin receptors, which are complexes of calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs). Its effects complement GLP-1 receptor agonists through entirely different pathways:
- Satiety Signaling: Activates hypothalamic satiety centers, reducing food intake through central nervous system mechanisms
- Gastric Emptying: Slows gastric emptying rate, reducing postprandial glucose excursions
- Glucagon Suppression: Reduces postprandial glucagon secretion
- Palate Conditioning: May reduce the reward value of food through central amylin pathways
Cagrilintide + Semaglutide Research
The combination of Cagrilintide (amylin analog) with semaglutide (GLP-1 agonist) is one of the most exciting areas in metabolic research. Because they operate through completely different receptor systems — amylin and GLP-1 — their effects on satiety, gastric emptying, and weight management are additive rather than competing. Early clinical research has shown the combination producing weight loss results that exceed either compound alone.
Research Applications
- Satiety Research: Studying amylin's role in appetite regulation and feeding behavior
- Combination Studies: Amylin + GLP-1 dual-pathway metabolic research
- Gastric Function: Effects on gastric emptying and postprandial metabolism
- Weight Management: Sustained satiety signaling and caloric intake reduction
Conclusion
Cagrilintide brings the amylin pathway to metabolic peptide research — a complementary mechanism to GLP-1 agonists. Its long-acting formulation and unique satiety mechanisms make it particularly valuable for combination research and studies examining the intersection of amylin signaling, appetite regulation, and metabolic function.
Source Research-Grade Cagrilintide
AltPeptide offers Cagrilintide in multiple research-grade formulations. All products are third-party assayed, lyophilized for stability, and shipped with DDP worldwide delivery.
All compounds are sold for laboratory research purposes only. Not for human or animal consumption.
All compounds mentioned are sold for in-vitro laboratory research only. Not for human or animal consumption. Not approved by FDA or any regulator for therapeutic use. This article is for educational and informational purposes only.